Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

If approved, the company is confident in its ability to Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

However, with lepodisiran, an experimental medication from drugmaker Eli Lilly, cardiologists may be one step closer to effectively treating the deadly form of cholesterol. Here’s what you need ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can “silence” the main gene responsible for ...